205 related articles for article (PubMed ID: 28501600)
1. Development of a human epidermal growth factor derivative with EGFR-blocking and depleted biological activities: A comparative in vitro study using EGFR-positive breast cancer cells.
Mehrabi M; Mansouri K; Soleymani B; Hoseinkhani Z; Shahlaie M; Khodarahmi R
Int J Biol Macromol; 2017 Oct; 103():275-285. PubMed ID: 28501600
[TBL] [Abstract][Full Text] [Related]
2. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
[TBL] [Abstract][Full Text] [Related]
3. Comparative experimental/theoretical studies on the EGFR dimerization under the effect of EGF/EGF analogues binding: Highlighting the importance of EGF/EGFR interactions at site III interface.
Mehrabi M; Mahdiuni H; Rasouli H; Mansouri K; Shahlaei M; Khodarahmi R
Int J Biol Macromol; 2018 Aug; 115():401-417. PubMed ID: 29665393
[TBL] [Abstract][Full Text] [Related]
4. Identification of a determinant of epidermal growth factor receptor ligand-binding specificity using a truncated, high-affinity form of the ectodomain.
Elleman TC; Domagala T; McKern NM; Nerrie M; Lönnqvist B; Adams TE; Lewis J; Lovrecz GO; Hoyne PA; Richards KM; Howlett GJ; Rothacker J; Jorissen RN; Lou M; Garrett TP; Burgess AW; Nice EC; Ward CW
Biochemistry; 2001 Jul; 40(30):8930-9. PubMed ID: 11467954
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
[TBL] [Abstract][Full Text] [Related]
6. Fusion of the CH1 domain of IgG1 to epidermal growth factor (EGF) prolongs its retention in the blood but does not increase tumor uptake.
Wang J; Reilly RM; Chen P; Yang S; Bray MR; Gariépy J; Chan C; Sandhu J
Cancer Biother Radiopharm; 2002 Dec; 17(6):665-71. PubMed ID: 12537670
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics simulations of epidermal growth factor and transforming growth factor-alpha structures in water.
Watts CR; Lovas S; Murphy RF
Proteins; 1998 Nov; 33(3):396-407. PubMed ID: 9829698
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy.
Fonge H; Lee H; Reilly RM; Allen C
Mol Pharm; 2010 Feb; 7(1):177-86. PubMed ID: 19924993
[TBL] [Abstract][Full Text] [Related]
9. Urinary transforming growth factors in neoplasia: separation of 125I-labeled transforming growth factor-alpha from epidermal growth factor in human urine.
Stromberg K; Hudgins WR
Cancer Res; 1986 Nov; 46(11):6004-10. PubMed ID: 3019543
[TBL] [Abstract][Full Text] [Related]
10. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
Reilly RM; Kiarash R; Cameron RG; Porlier N; Sandhu J; Hill RP; Vallis K; Hendler A; Gariépy J
J Nucl Med; 2000 Mar; 41(3):429-38. PubMed ID: 10716315
[TBL] [Abstract][Full Text] [Related]
11. A single amino acid exchange, Arg-45 to Ala, generates an epidermal growth factor (EGF) mutant with high affinity for the chicken EGF receptor.
van de Poll ML; Lenferink AE; van Vugt MJ; Jacobs JJ; Janssen JW; Joldersma M; van Zoelen EJ
J Biol Chem; 1995 Sep; 270(38):22337-43. PubMed ID: 7673217
[TBL] [Abstract][Full Text] [Related]
12. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
[TBL] [Abstract][Full Text] [Related]
13. pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes.
Maeda K; Kato Y; Sugiyama Y
J Control Release; 2002 Jul; 82(1):71-82. PubMed ID: 12106978
[TBL] [Abstract][Full Text] [Related]
14. 5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells.
Lan KH; Shih YS; Chang CA; Yen SH; Lan KL
Biochem Biophys Res Commun; 2012 Nov; 428(2):292-7. PubMed ID: 23085230
[TBL] [Abstract][Full Text] [Related]
15. Contribution of the transforming growth factor alpha B-loop beta-sheet to binding and activation of the epidermal growth factor receptor.
Richter A; Drummond DR; MacGarvie J; Puddicombe SM; Chamberlin SG; Davies DE
J Biol Chem; 1995 Jan; 270(4):1612-6. PubMed ID: 7829492
[TBL] [Abstract][Full Text] [Related]
16. Critical effects on binding of epidermal growth factor produced by amino acid substitutions.
Mehrabi M; Khodarahmi R; Shahlaei M
J Biomol Struct Dyn; 2017 Apr; 35(5):1085-1101. PubMed ID: 27212100
[TBL] [Abstract][Full Text] [Related]
17. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
Cornelissen B; Darbar S; Hernandez R; Kersemans V; Tullis I; Barber PR; Smart S; Vojnovic B; Reilly R; Vallis KA
J Nucl Med; 2011 May; 52(5):776-83. PubMed ID: 21498540
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of the growth-inhibitory effect of the RNase-EGF fused protein against EGFR-overexpressing cells.
Hoshimoto S; Ueda M; Jinno H; Kitajima M; Futami J; Seno M
Anticancer Res; 2006; 26(2A):857-63. PubMed ID: 16619480
[TBL] [Abstract][Full Text] [Related]
19. Conformational characterization of a single-site mutant of murine epidermal growth factor (EGF) by 1H NMR provides evidence that leucine-47 is involved in the interactions with the EGF receptor.
Moy FJ; Scheraga HA; Liu JF; Wu R; Montelione GT
Proc Natl Acad Sci U S A; 1989 Dec; 86(24):9836-40. PubMed ID: 2690076
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of chemomigration of a human prostatic carcinoma cell (TSU-pr1) line by inhibition of epidermal growth factor receptor function.
Zolfaghari A; Djakiew D
Prostate; 1996 Apr; 28(4):232-8. PubMed ID: 8602399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
